Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis

References

• Leonardi A, Castegnaro A, Valerio ALG, Lazzarini D. Epidemiology of allergic conjunctivitis: clinical appearance and treatment patterns in a population-based study. Curr Opin Allergy Clin Immunol. 2015;15(5):482–488. doi:10.1097/ACI.0000000000000204
   PubMed Web of Science ®Google Scholar
• Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:471–476. doi:10.1097/ACI.0b013e32834a9676
   PubMed Web of Science ®Google Scholar
• Miyazaki D, Fukagawa K, Okamoto S, et al. Epidemiological aspects of allergic conjunctivitis. Allergol Int. 2020;69(4):487–495. doi:10.1016/j.alit.2020.06.004
   PubMed Web of Science ®Google Scholar
• Bergmann MT, Williams JI, Gomes PJ. Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%. Clin Ophthalmol. 2014;8:1495–1505. doi:10.2147/OPTH.S66637
   PubMedGoogle Scholar
• Phipatanakul W. Allergic rhinoconjunctivitis: epidemiology. Immunol Allergy Clin North Am. 2005;25(2):263–281. doi:10.1016/j.iac.2005.03.001
   PubMed Web of Science ®Google Scholar
• Bielory L, Delgado L, Katelaris CH, Leonardi A, Rosario N, Vichyanoud P. ICON: diagnosis and management of allergic conjunctivitis. Ann Allergy Asthma Immunol. 2019;124:118–134. doi:10.1016/j.anai.2019.11.014
   PubMed Web of Science ®Google Scholar
• Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A. Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis. Cochrane Database Syst Rev. 2015;2015(6). doi:10.1002/14651858.CD009566.pub2
   PubMedGoogle Scholar
• Andoh T, Kuraishi Y. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur J Pharmacol. 2006;547(1–3):59–64. doi:10.1016/j.ejphar.2006.07.009
   PubMed Web of Science ®Google Scholar
• Kida T, Fujii A, Sakai O, et al. Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res. 2010;91(1):85–91. doi:10.1016/j.exer.2010.04.006
   PubMed Web of Science ®Google Scholar
• Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a Phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen cha. Clin Ther. 2009;31(9):1908–1921. doi:10.1016/j.clinthera.2009.09.001
   PubMed Web of Science ®Google Scholar
• Macejko TT, Bergmann MT, Williams JI, et al. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am J Ophthalmol. 2010;150(1):122–127. doi:10.1016/j.ajo.2010.02.007
   PubMed Web of Science ®Google Scholar
• Williams JI, Kennedy KS, Gow JA, et al. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis. J Ocul Pharmacol Ther. 2011;27(4):385–393. doi:10.1089/jop.2011.0005
   PubMed Web of Science ®Google Scholar
• Torkildsen GL, Gomes PJ, Williams JI, Gow JA, McNamara TR. Bepotastine besilate ophthalmic solution 1.5% reduces ocular itching in a clinical model of allergic conjunctivitis. J Allergy Clin Immunol. 2009;123(2):S57. doi:10.1016/j.jaci.2008.12.186
   Web of Science ®Google Scholar
• Iordache A, Boruga M, Mușat O, Jipa DA, Tătaru CP, Mușat GC. Relationship between allergic rhinitis and allergic conjunctivitis (allergic rhinoconjunctivitis) - review. Rom J Ophthalmol. 2022;66(1):8–12. doi:10.22336/rjo.2022.3
   PubMedGoogle Scholar
• Berger W, Abelson MB, Gomes PJ, et al. Effects of adjuvant therapy with 0. 1 % olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol. 2005;95(4):361–371. doi:10.1016/S1081-1206(10)61155-6
   PubMed Web of Science ®Google Scholar
• Bousquet J, Knani J, Hejjaoui A, Ferrando R, Cour P, Dhivert H. Heterogeneity of atopy. I. Clinical and immunologic characteristics of patients allergic to cypress pollen. Allergy. 1993;48:183–188. doi:10.1111/j.1398-9995.1993.tb00711.x
   PubMed Web of Science ®Google Scholar
• Cavet ME, Gomes PJ, Carr WW, Williams JI. Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis. J Asthma Allergy. 2018;11:29–39. doi:10.2147/JAA.S160687
   PubMed Web of Science ®Google Scholar
• Torkildsen GL, Williams JI, Gow JA, Gomes PJ, Abelson MB, McNamara TR. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann Allergy Asthma Immunol. 2010;105(1):57–64. doi:10.1016/j.anai.2010.04.005
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye. 2022;36(2):361–368. doi:10.1038/s41433-021-01668-x
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010;27(11):837–845. doi:10.1007/s12325-010-0070-1
   PubMed Web of Science ®Google Scholar
• Ayaki M, Iwasawa A. Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines. Clin Ophthalmol. 2010;4(1):919–924. doi:10.2147/OPTH.S13406
   PubMedGoogle Scholar
• Pauly A, Brasnu E, Riancho L, Brignole-Baudouin F, Baudouin C. Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Mol Vis. 2011;17:745–755.
   PubMed Web of Science ®Google Scholar
• Epstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther. 2009;25(2):113–119. doi:10.1089/jop.2008.0098
   PubMed Web of Science ®Google Scholar
• Tau J, Aguilar A, Berra A, Del Papa M, Passerini MS. Cytotoxicity evaluation of a novel latanoprost 0.005% nanoemulsion. Poster presentado en: 2021 European Association for Vision and Eye Research Virtual Congress; 2021.
   Google Scholar
• Baudouin C, Denoyer A, Desbenoit N, Hamm G, Grise A. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (An American Ophthalmological Society Thesis). Trans Am Ophtalmol Soc. 2012;110:40–63.
   PubMedGoogle Scholar
• Izzotti A, La Maestra S, Micale RT, Longobardi MG, Saccà SC. Genomic and post-genomic effects of anti-glaucoma drugs preservatives in trabecular meshwork. Mutat Res. 2015;772:1–9. doi:10.1016/j.mrfmmm.2014.11.006
   PubMed Web of Science ®Google Scholar
• Ammar DA, Kahook MY. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br J Ophthalmol. 2011;95(10):1466–1469. doi:10.1136/bjophthalmol-2011-300012
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther. 2008;25(8):743–751. doi:10.1007/s12325-008-0078-y
   PubMed Web of Science ®Google Scholar
• Hedengran A, Freiberg JC, Hansen PM, et al. Generic benzalkonium chloride-preserved travoprost eye drops are not identical to the branded polyquaternium-1-preserved travoprost eye drop: effect on cultured human conjunctival goblet cells and their physicochemical properties. Acta Ophthalmol. 2022;100(7):819–827. doi:10.1111/aos.15163
   PubMed Web of Science ®Google Scholar
• Nagai N, Murao T, Okamoto N, Ito Y. Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium. J Oleo Sci. 2010;59(3):135–141. doi:10.5650/jos.59.135
   PubMed Web of Science ®Google Scholar
• Liang H, Brignole-Baudouin F, Riancho L, Baudouin C. Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions. Ophthalmic Res. 2012;48(2):89–101. doi:10.1159/000335984
   PubMed Web of Science ®Google Scholar
• Pauly A, Meloni M, Bringole-Baudouin F, Warnet JM, Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci. 2009;50:2644. doi:10.1167/iovs.08-2992
   Web of Science ®Google Scholar
• Kim JH, Kim EJ, Kim YH, et al. In vivo effects of preservative-free and preserved prostaglandin analogs: mouse ocular surface study. Korean J Ophthalmol. 2015;29(4):270–279. doi:10.3341/kjo.2015.29.4.270
   PubMedGoogle Scholar
• Pisella PJ, Pouliquen P, Baudouin C, Grasso CM. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–423. doi:10.1136/bjo.86.4.418
   PubMed Web of Science ®Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341–349. doi:10.1177/112067210701700311
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445–454. doi:10.2147/OPTH.S91402
   PubMed Web of Science ®Google Scholar
• Huang C, Wang H, Pan J, et al. Benzalkonium chloride induces subconjunctival fibrosis through the COX-2-modulated activation of a TGF-β1/Smad3 signaling pathway. Investig Ophthalmol Vis Sci. 2014;55(12):8111–8122. doi:10.1167/iovs.14-14504
   PubMed Web of Science ®Google Scholar
• Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106(3):556–563. doi:10.1016/S0161-6420(99)90116-1
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–355. doi:10.1097/IJG.0b013e31815c5f4f
   PubMed Web of Science ®Google Scholar
• Casiraghi JF, Grigera D, Alejo Peyret J, Del Papa M, Passerini MS. Efficacy and tolerability of a new latanoprost 0.005% BAK-free nanoemulsion: a nonrandomized open-label trial. ReGEN Open. 2021;1(1):110–116.
   Google Scholar
• Nelson JD. Impression Cytology. Cornea. 1988;7(1):71–81. doi:10.1097/00003226-198801000-00012
   PubMed Web of Science ®Google Scholar
• Abelson MB, Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Curr Allergy Asthma Rep. 2003;3(4):363–368. doi:10.1007/s11882-003-0100-z
   PubMed Web of Science ®Google Scholar
• Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16(1). doi:10.1186/s13223-020-0403-9
   PubMed Web of Science ®Google Scholar
• Kato M, Nishida A, Aga Y, et al. Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent bepotastine besilate. Arzneimittel. 1997;47(10):1116–1124.
   PubMed Web of Science ®Google Scholar
• Carrillo-martin I, Gonzalez-estrada A, Dimov V. Bepotastine besilate for the treatment of perennial allergic rhinitis. Expert Opin Pharmacother. 2018;19(15):1727–1730. doi:10.1080/14656566.2018.1519020
   PubMed Web of Science ®Google Scholar
• Williams JI, Gow JA, Klier SM, McCue SL, Salapatek AMF, McNamara TR. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin. 2010;26(10):2329–2338. doi:10.1185/03007995.2010.486753
   PubMed Web of Science ®Google Scholar
• Carr WW, Nayak AS, Ratner PH, Gow JA, McNamara TR, Williams JI. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial. Allergy Asthma Proc. 2013;34(3):247–254. doi:10.2500/aap.2013.34.3671
   PubMed Web of Science ®Google Scholar
• Ayyappanavar S, Sridhar S, Kumar K, et al. Comparative analysis of safety and efficacy of alcaftadine 0.25%, olopatadine hydrochloride 0.2% and bepotastine besilate 1.5% in allergic conjunctivitis. Indian J Ophthalmol. 2021;69(2):257–261. doi:10.4103/ijo.IJO_2083_20
   PubMed Web of Science ®Google Scholar
• McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin Ophthalmol. 2012;6(1):1731–1738. doi:10.2147/OPTH.S35431
   PubMedGoogle Scholar
• Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334. doi:10.1016/j.preteyeres.2010.03.001
   PubMed Web of Science ®Google Scholar
• Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in glaucoma: from the back to the front of the eye, and beyond. Prog Retin Eye Res. 2021;83:100916. doi:10.1016/j.preteyeres.2020.100916
   PubMed Web of Science ®Google Scholar